John T. Treace, Chief Executive Officer, 10% Owner at TREACE MEDICAL CONCEPTS, INC. (TMCI), bought 55,944 shares at $4.44 ($247K) on 2026-08-20, disclosed to the SEC on 2026-08-24.
CEO John T. Treace purchased 39,944 shares for $177,176, signaling confidence in the company's turnaround despite recent revenue declines. This insider buying comes as the stock has rallied 55% over the last 90 days.
The stock is down 3.22% over the last 5 days but has surged 55.06% over the last 90 days, trading at $4.365, which is 269.92% above its 52-week low of $1.18.
Q2 2026 earnings on August 7, 2026, where the company reported a 4% revenue decline but raised full-year guidance on strong adoption of new bunion systems.
The stock faces a risk of continued revenue pressure due to lower procedure-kit sales to stocking distributors and a shift toward lower-priced minimally invasive products.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.44 | 39,944 | $177K | 71.8% |
| 2 | $4.35 | 5,000 | $22K | 8.8% |
| 3 | $4.34 | 11,000 | $48K | 19.4% |
| Total | $4.41 avg | 55,944 | $247K | 100% |
| Filing → |
| TMCI | BUY | 2026-06-01 | $178K | — | Filing → |
| TMCI | BUY | 2026-05-28 | $341K | — | Filing → |
| TMCI | BUY | 2026-05-14 | $376K | — | Filing → |